30.32
3.06%
0.90
Handel nachbörslich:
28.81
-1.51
-4.98%
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
6.20%
8.379
|
8.933 | 3.572 | 4.065 | 3.48 |
Operating Expenses |
31.40%
80.88
|
61.55 | 61.80 | 78.48 | 64.26 |
Benefits Costs and Expenses |
38.05%
83.47
|
60.46 | 61.78 | 78.01 | 63.90 |
Costs And Expenses |
38.05%
83.47
|
60.46 | 61.78 | 78.01 | 63.90 |
Provision For Loan, Lease, And Other Losses |
-
|
- | - | - | - |
Operating Income/Loss |
37.78%
-72.50
|
-52.62 | -58.23 | -74.41 | -60.78 |
Net Interest Income/Expense |
6.20%
8.379
|
8.933 | 3.572 | 4.065 | 3.48 |
Interest Income/Expense After Provision For Losses |
6.20%
8.379
|
8.933 | 3.572 | 4.065 | 3.48 |
Income/Loss From Continuing Operations Before Tax |
45.73%
-75.09
|
-51.53 | -58.21 | -73.95 | -60.42 |
Income Tax Expense/Benefit |
314.81%
0.232
|
-0.108 | 0.454 | -0.011 | -0.991 |
Income/Loss From Continuing Operations After Tax |
46.48%
-75.32
|
-51.42 | -58.66 | -73.94 | -59.43 |
Net Income/Loss
|
46.48%
-75.32
|
-51.42 | -58.66 | -73.94 | -59.43 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
98.25%
2.5233
|
144.52 | 131.16 | 130.50 | 2.41 |
Diluted Average Shares |
98.25%
2.5233
|
144.52 | 131.16 | 130.50 | 2.41 |
Basic Earnings Per Share |
44.44%
-0.52
|
-0.36 | -0.45 | -0.57 | -0.45 |
Diluted Earnings Per Share |
44.44%
-0.52
|
-0.36 | -0.45 | -0.57 | -0.45 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):